Octapharma GmbH, based in Langenfeld, acts as the German distribution subsidiary of the Octapharma Group, specializing in the distribution of plasma derivatives and recombinant coagulation factors. The company primarily serves the immunology, haemophilia, and intensive care market segments, supplying products to wholesalers, pharmacies, and hospitals. With a workforce of 56 employees, the company manages its operations through a key performance indicator system closely linked to sales volumes and revenue. Research and development are conducted centrally by the parent company, Octapharma AG, in Switzerland.
Der Import, die Herstellung und der Vertrieb von pharmazeutischen und medizinisch-technischen Erzeugnissen, insbesondere von Plasmaderivaten.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 45770 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Uwe Münster | Geschäftsführer(in) | Langenfeld |
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 45770 (as of 30 October 2026)
| Date | Contract | Value |
|---|---|---|
| 29.9.2026 | Supplier · AOK Baden-Württemberg | — |
| 17.9.2026 | Supplier · PBMG eG | — |
| 3.9.2026 | Arzneimittelrabattvertrag nach § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V zu den Arzneimitteln Nuwiq (B02BD02), Octanate (B02BD02), Octanine F (B02BD04) und Wilate (B02BD06) bei Hämophilie Supplier · AOK Sachsen - Anhalt | — |
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | €261,134,355 | €6,753,350 | €73,158,151 | — |
| 2024 | €228,514,456 | €5,176,368 | €74,014,547 | — |
| 2023 | €252,135,093 | €6,144,976 | €55,270,003 | — |
| 2022 | €253,144,093 | €6,322,237 | €48,147,808 | — |
| 2021 | €227,636,521 | €6,088,668 | €42,381,965 | — |
| 2020 | €207,233,377 | €5,673,533 | €53,526,778 | — |
| 2019 | €212,935,482 | €5,751,407 | €51,993,926 | — |
| 2018 | €182,837,689 | €4,863,698 | €44,450,699 | — |
| 2017 | €161,892,959 | €4,388,972 | €48,639,335 | — |
| 2016 | €139,202,746 | -€2,069,592 | €37,188,023 | — |
Sign in to download data
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 45770 (as of 30 October 2026)
INFECTOPHARM Arzneimittel und Consilium GmbH
Heppenheim · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
IDT Biologika GmbH
Dessau-Roßlau · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
LTS LOHMANN Therapie-Systeme AG.
Andernach · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €6,260,919 | 2.6% |
| Material Costs | €236,985,363 | 97.3% |
| Depreciation | €379,103 | 0.2% |
| Interest & Similar | €5,019 | 0.0% |
